CWP
NBIX icon

Concord Wealth Partners’s Neurocrine Biosciences NBIX Stock Holding History

Concord Wealth Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-84
Closed -$9.45K – 950
2023
Q3 		$9.45K Hold
84
– – ﹤0.01% 627
2023
Q2 		$7.92K Hold
84
– – ﹤0.01% 641
2023
Q1 		$8.5K Hold
84
– – ﹤0.01% 610
2022
Q4 		$10K Buy
+84
New +$9.84K ﹤0.01% 634
2022
Q3 		– Sell
-84
Closed -$8K – 763
2022
Q2 		$8K Hold
84
– – ﹤0.01% 738
2022
Q1 		$8K Hold
84
– – ﹤0.01% 824
2021
Q4 		$7K Hold
84
– – ﹤0.01% 877
2021
Q3 		$8K Sell
84
-37
-31% -$3.5K ﹤0.01% 505
2021
Q2 		$12K Buy
121
+66
+120% +$6.33K ﹤0.01% 597
2021
Q1 		$5K Buy
+55
New +$5.77K ﹤0.01% 672

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Concord Wealth Partners's NBIX Position: Q4 2023 in Review

Concord Wealth Partners sold out of Neurocrine Biosciences (NBIX) in Q4 2023, closing a stake of 84 shares — an estimated $9.45K sold.

Concord Wealth Partners first reported a position in NBIX in Q1 2021 and held it in 10 quarters. The position peaked at $12K in Q2 2021. 554 funds tracked by Wall St. Rank hold NBIX as of Q4 2023.

  • Concord Wealth Partners reported no remaining Neurocrine Biosciences position as of Q4 2023 after selling out during the quarter.
  • Concord Wealth Partners sold 84 Neurocrine Biosciences shares in Q4 2023, an estimated $9.45K.
  • Concord Wealth Partners first reported a position in Neurocrine Biosciences in Q1 2021 and held it in 10 quarters.
  • Concord Wealth Partners's Neurocrine Biosciences position peaked at $12K in Q2 2021.
  • 554 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2023.

Based on Concord Wealth Partners's 13F filing for Q4 2023, filed 6 Feb 2024.